Trials / Completed
CompletedNCT01018875
Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease
A Randomized, Double-Blind, Active- and Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 242 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 55 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy and safety study of ABT-288 in adults with mild-to-moderate Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-288 | Subjects will take 4 capsules once daily for 12 weeks. |
| DRUG | donepezil | Subjects will take 4 capsules once daily for 12 weeks. |
| DRUG | placebo | Subjects will take 4 capsules once daily for 12 weeks. |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2011-02-01
- Completion
- 2011-02-01
- First posted
- 2009-11-24
- Last updated
- 2018-06-06
Locations
21 sites across 2 countries: Russia, Ukraine
Source: ClinicalTrials.gov record NCT01018875. Inclusion in this directory is not an endorsement.